What is Combivir?
• Combivir is an HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs). Combivir prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body. • Combivir is marketed by GlaxoSmithKline. It was approved by the U.S. Food and Drug Administration (FDA) for use by people living with HIV in 1997. • Combivir is a combination of two drugs: 300mg of Retrovir (zidovudine) and 150mg of Epivir (lamivudine). Combivir should be prescribed by a healthcare provider for patients who need both of these drugs. Both of these drugs can still be purchased individually for use in combination with other HIV drugs. • Combivir must be combined with at least one other HIV drug, usually a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). • GlaxoSmithKline has established a patient assistance program (PAP) for people liv
